12-06-01

IDS/#9\$

PATENT

ATTORNEY DOCKET NO.: TNX00-04

CUSTOMER NO: 26839

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of: FUNG, Michael, et al.)) Group Art Unit: 1645
Serial No.: 09/816,839))) Examiner: TO BE ASSIGNED
Filed: March 23, 2001)
For: ANTI C2/C2a INHIBITORS OF COMPLEMENT ACTIVATION	REC TECH CEN
Assistant Commissioner for Patents Washington, D.C. 20231	ECEIVED DEC 1 0 2001 CENTER 1600/2900
Dear Sir:	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants submit the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed to the best of Applicant's knowledge before the first Office Action on the merits. These references were cited in the International Search Report of the foreign counterpart dated August 28, 2001. Please charge the fee of \$180.00 to our Deposit Account 20-0087.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached PTO 1449 form.

This submission does not represent that a search has been made or that no other documents exist which may be material to the examination of this application and

Attorney Docket No.: TNX 00-04 Customer No.: 26839

does not constitute an admission that any of the listed documents, or any part thereof, are material or constitute prior art under title 35 of the United States code. Applicants reserve the right to present evidence that any of such documents are not prior art.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully Submitted,

Dated: October 31, 2001.

Cheryl A. Liljestrand

Reg. No. 45,275